DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI

Stock Information for DMK Pharmaceuticals Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About DMK Pharmaceuticals Corporation

DMK Pharmaceuticals Commences Restructuring Proceeding
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023
DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)
DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)
DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.